Given the observation that PTEN deletion is a mechanism for MEKi resistance in solid tumours [21, 22], and that deletion of PTEN in AML is sufficient to confer resistance, we propose that this event can be used as a biomarker of MEK inhibitor resistance in AML. This evidence concerns the gene PTEN and acute myeloid leukemia.